production, biodistribution assessment and dosimetric evaluation of 177lu-tthmp as a bone pain palliation agent
Authors
abstract
objective(s): recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. although 177lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177lu- tthmp), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. in this study, production, quality control, biodistribution, and dose evaluation of 177lu-tthmp have been investigated and compared with the previously reported data. methods: tthmp was synthesized and characterized, using spectroscopic methods. radiochemical purity of the 177lu-tthmp complex was determined using instant thin-layer chromatography (itlc) and high performance liquid chromatography (hplc) methods. the complex was injected to wild-type rats and biodistribution was studied for 7 days. preliminary dose evaluation was investigated based on biodistribution data in rats. results: 177lu was prepared with 2.6-3 gbq/mg specific activity and radionuclide purity of 99.98%. 177lu-tthmp was successfully prepared with high radiochemical purity (>99%). the complex showed rapid bone uptake, while accumulation in other organs was insignificant. dosimetric results showed that all tissues received almost insignificant absorbed doses in comparison with bone tissues. conclusion: based on the obtained results, this radiopharmaceutical can be a good candidate for bone pain palliation therapy in skeletal metastases.
similar resources
Production, biodistribution assessment and dosimetric evaluation of 177Lu-TTHMP as a bone pain palliation agent
Objective(s): Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although 177Lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177Lu- TTHMP), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. In this study,...
full textProduction, biodistribution assessment and dosimetric evaluation of 177Lu-TTHMP as an agent for bone pain palliation
OBJECTIVES Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although (177)Lu-triethylene tetramine hexa methylene phosphonic acid (abbreviated as (177)Lu-TTHMP), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. In this study...
full textProduction, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent
Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: 153Sm-TTHMP was prepared starting from 153<...
full textProduction, quality control, and biodistribution studies of 141Ce-EDTMP as a potential bone pain palliation agent
The purpose of the present work was to introduce 141Ce-EDTMP as a novel potential future pain palliative agent to patients suffering from disseminated skeletal metastases and diagnostic imaging radioisotope as well. Cerium-141 [T1/2 = 32.501 days, Eβ (max) = 0.580 (29.8%) and 0.435(70.2%) MeV, Eγ = 145.44 (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of ...
full textProduction, quality control and biological evaluation of Sm-TTHMP as a possible bone palliation agent
Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: Sm-TTHMP was prepared starting from Sm-SmCl3, prepared by neutron activati...
full textproduction, quality control and biological evaluation of 153sm-tthmp as a possible bone palliation agent
introduction: various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153sm-edtmp. in this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. methods: 153sm-tthmp was prepared starting from 153sm-smcl3, prepared by neutro...
full textMy Resources
Save resource for easier access later
Journal title:
asia oceania journal of nuclear medicine and biologyجلد ۳، شماره ۱، صفحات ۳۵-۴۲
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023